BYN-001 / Bionyra Pharma, NovaRock Biotherapeutics, CSPC Pharma - LARVOL DELTA

Bionyra Pharma…announced that the first healthy volunteers have been dosed in the Phase 1 study of BYN-001, the company's long-acting anti-IL-25 monoclonal antibody being developed for atopic dermatitis (Businesswire) - "The study, designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamic profile of BYN-001 in healthy volunteers, has been initiated in Australia, with the first cohort of healthy volunteers enrolled in the single ascending dose (SAD) portion of the trial."

Trial status • Atopic Dermatitis

BYN-001-101: A Study of BYN-001 in Healthy Adults and in Adults With Moderate to Severe Atopic Dermatitis (clinicaltrials.gov) - P1 | N=56 | Not yet recruiting | Sponsor: Bionyra Pharma

First-in-human • New P1 trial • Atopic Dermatitis • Dermatitis • Dermatology • Immunology